Urologic Oncology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York.
NEJM Evid. 2023 Jan;2(1):EVIDe2200264. doi: 10.1056/EVIDe2200264. Epub 2022 Dec 27.
For more than 40 years, intravesical Bacillus Calmette-Guérin (BCG) has remained the most effective treatment for non-muscle-invasive bladder cancer (NMIBC); however, tumor recurrence and progression are common, especially for those patients with carcinoma in situ (CIS). Therapeutic options are limited when treatment with BCG fails, and radical cystectomy remains the only curative treatment. BCG-unresponsive NMIBC criteria were developed in 2015 to identify patients for whom additional BCG would likely not be effective and to facilitate clinical trials of novel therapies..
40 多年来，膀胱内卡介苗（BCG）一直是治疗非肌肉浸润性膀胱癌（NMIBC）最有效的方法；然而，肿瘤复发和进展很常见，特别是对于那些患有原位癌（CIS）的患者。当 BCG 治疗失败时，治疗选择有限，根治性膀胱切除术仍然是唯一的治愈性治疗方法。2015 年制定了 BCG 无应答 NMIBC 标准，以确定哪些患者可能对额外 BCG 治疗无效，并促进新型治疗方法的临床试验。
